Follow-up Schedule for Patients With Sentinel Node–negative Cutaneous Melanoma (The MELFO Study)

Abstract

A reduced-intensity, American Joint Committee on Cancer (AJCC) stage-adjusted follow-up schedule for sentinel node-negative melanoma patients is a safe strategy, and patient self-examination is effective for recurrence detection with no evidence of diagnostic delay. Patients' acceptance is very high.